Small Cap Feast

30th November 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
No joiners today.

Leavers: 
No leavers today.





What’s Cooking In The IPO Kitchen?

30 November: Flex Labs ITF: a software business engaged in the development of advanced artificial intelligence (AI) middleware products, intending to offer these to business customers through a software as a service (SaaS) model announces its application for Admission to the AQSE Growth Market. Expected AQSE Admission date is on or around the 15 December 2023.

23 November — Substrate Artificial Intelligence ITF: An artificial intelligence Company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health announces its Admission to the Aquis Growth Market. Expected Admission date is on or around the 7 December 2023.

15 November: Afentra Plc ITF: Formerly Sterling Energy plc, and launched in 2021 to support the African energy transition as a independent oil and gas company announces its Admission to AIM pursuant to the Sonangol Acquisition which constitutes a reverse takeover and therefore Admission is being sought as a result of such reverse take-over. The Company will not be raising new capital as part of its Admission. Anticipated market capitalisation on Admission will be c.£65m. Expected Admission date is expected mid-December.

9 November: Chapel Down Group ITF:  England's leading and largest wine producer with an award-winning range of sparkling and still wines, under the Chapel Down brand. The Company owns, leases and sources from 1,023 acres of vineyards in South East England announces its Admission to AIM after its transfer from the Aquis Apex market. The Company will not be raising new capital or providing a secondary offering as part of its Admission. Anticipated market capitalisation on Admission will be c.£75m. Expected Admission date is 7 December 2023.

2 October: Tekcapital announced intention to spin off and IPO: MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-November.


Breakfast Buffet

Ariana Resources 2.45p £28.1m (AAU.L)
The mineral exploration and development Company with gold mining interests in Europe announces a further set of results from the ongoing drilling programme at Salinbas. Completion of resource drilling within the upper Salinbas area resulted in completion of 5,928.8 metres, for 61 diamond holes since January 2023 and 2,006 samples for 1,744.5 metres of drill core are still pending for assay analysis at the Kiziltepe Mine Laboratory. Key intercepts from the latest batch of results include: 1) SALH093: 7.2m @ 9.37g/t Au + 19.6g/t Ag - from 86.2 metres including 1.4m @ 35.02g/t Au + 69.8g/t Ag - from 88.7 metres, 2) SALH092: 6.5m @ 3.69g/t Au + 4.4g/t Ag - from 108.1 metres and 3) SALH102: 11.05m @ 1.56g/t Au + 11.8g/t Ag - from 85.35 metres.

DXS International* 2.75p £1.8m (AQSE: DXSP)
The clinical decision support developer and supplier of clinical decision support systems announces its success in securing £409k of grant funding jointly with Health Innovation East from Innovate UK – the UK’s national innovation agency. The Innovate UK grant will enable DXS to accelerate its efforts in advancing ExpertCare. The funds channeled into intensive research, prototyping, and testing will pave the way for ExpertCare’s ongoing development and route to market. The Innovate UK, DXS and Health Innovation East R&D project (funded for 18- months) will consist of two primary elements: 1) A comprehensive cost-to-benefit analysis in the form of a real-world evaluation led by the Health Innovation East to evaluate ExpertCare's utility within a clinical environment. 2) The development and prototyping of two additional cardiovascular related long-term condition AI algorithms, namely diabetes and hypercholesterolemia, together with common relevant comorbidities.

genedrive 6p £6.5m (GDR.L)
The near patient molecular diagnostics Company announces its audited final results for the year ended 30 June 2023. The loss for the year was £5.2m (2022: loss of £4.7m), R&D spend of £3.9m (2022: £3.9m) and the Company has cash at bank of £2.6m (2022: £4.6m). Genedrive MT-RNR1 ID Test receives positive final recommendation in NICE's Early Value Assessment programme and its MT-RNR1 has commenced rollout in Greater Manchester hospitals. The Company announces its pre-submission process is ongoing with the Food and Drug Administration to determine regulatory process and requirements to place Antibiotic Induced Hearing Loss into the American market.

Global Petroleum 0.068p £0.9m (GBP.L)
An oil and gas upstream exploration Company presently focused on Africa and the Mediterranean announces that it has raised £253k in aggregate before costs through a Placing of new Ordinary Shares at a Price of 0.06 pence per share (Fundraise). The Price represents a discount of 29% to the closing price on 29 November 2023. The primary purpose of the Fundraise is to ensure that the liabilities in relation to the obligations of the Company's Walvis Basin licence PEL94 are completed to pre-agreed timelines set by the Namibia Government.

Microlise Group 97.5p £113.0m (SAAS.L)
A provider of SaaS based transport technology solutions to fleet operators announces that it has reached an agreement to acquire Enterprise Software Systems (ESS), a provider of transportation management system solutions. Under the terms, Microlise will pay an initial £7.65m cash payment and a maximum deferred contingent consideration of £0.85m, payable in cash after 6 months from completion. The vendors will also receive a further £3m from existing ESS cash reserves on completion so that the Company acquires the business on an effective cash and debt free basis. The acquisition is expected to immediately enhance earnings on completion.

Poolbeg Pharma* 9.35p £46.8m (POLB.L)
A biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need announces that Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director will become Chair of the Remuneration Committee.

Proteome Sciences 4.76p £14.1m (PRM.L)
A provider of contract proteomics services to enable drug discovery, development and biomarker identification expects the US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory. The Company is also engaged in discussions with several pharmaceutical companies and academic groups regarding single cell proteomics projects and hopes to initiate studies early in 2024. The Company now expects to report reduced revenues for the full year 2023, which will be lower than FY 2022, as a result the Company expects to report a net loss for the full year 2023. In 2024, the Company expects a more positive environment.

SkinBioTherapeutics 18.75p £35.7m (SBTX.L)
The life science business focused on skin health announces that its AxisBiotix-Ps food supplement will launch on Amazon.co.uk on 6 December . The launch of a sales channel through Amazon is a key part of the commercialisation strategy to expand market share for AxisBiotix-Ps. AxisBiotix-Ps first went on sale in the UK in October 2021 and is intended for customers to alleviate sensitive skin conditions such as psoriasis.

Wynnstay Group 372.5p £85.5m (WYN.L)
The agricultural supplies and merchanting group provides an update on trading for the financial year ended 31 October 2023 (FY23). The trading environment in the second half of the financial year was more difficult than the first, with lower farm-gate prices adversely affecting farmer spending patterns. In addition, the seasonally critical final quarter has been impacted by abnormally wet weather. As a result, the Group's results for the financial year are now expected to be below current market expectations. The Board still anticipates that the next financial year will show an improvement over FY23.

Zoo Digital Group 59p £57.7m (ZOO.L)
A provider of cloud-based localisation and digital media services to the global entertainment industry announces its unaudited financial results for the six months ended 30 September 2023 (H1 FY24). Revenues decreased by 58% to $21.4m (H1 FY23: $51.4m) primarily as a result of the Hollywood writers' and actors' strikes. The gross profit decreased by 87% to $2.1m (H1 FY23: $16.5m) and adjusted LBITDA was $7.1m (H1 FY23: EBITDA of $7.3m). The operating loss came in at $10.9m (H1 FY23: $3.8m operating profit), and the Company holds a cash balance of £16.8m at the period end. The Company expects to achieve at least break-even at the EBITDA level in Q4 and return to profitability in FY25 in line with current market expectations.

30 November 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram